1. Home
  2. ENTX vs IMRX Comparison

ENTX vs IMRX Comparison

Compare ENTX & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENTX
  • IMRX
  • Stock Information
  • Founded
  • ENTX 2010
  • IMRX 2008
  • Country
  • ENTX Israel
  • IMRX United States
  • Employees
  • ENTX N/A
  • IMRX N/A
  • Industry
  • ENTX Biotechnology: Biological Products (No Diagnostic Substances)
  • IMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ENTX Health Care
  • IMRX Health Care
  • Exchange
  • ENTX Nasdaq
  • IMRX Nasdaq
  • Market Cap
  • ENTX 69.6M
  • IMRX 62.7M
  • IPO Year
  • ENTX 2018
  • IMRX 2021
  • Fundamental
  • Price
  • ENTX $1.67
  • IMRX $1.50
  • Analyst Decision
  • ENTX Strong Buy
  • IMRX Strong Buy
  • Analyst Count
  • ENTX 1
  • IMRX 3
  • Target Price
  • ENTX $10.00
  • IMRX $11.00
  • AVG Volume (30 Days)
  • ENTX 46.7K
  • IMRX 162.6K
  • Earning Date
  • ENTX 03-28-2025
  • IMRX 03-20-2025
  • Dividend Yield
  • ENTX N/A
  • IMRX N/A
  • EPS Growth
  • ENTX N/A
  • IMRX N/A
  • EPS
  • ENTX N/A
  • IMRX N/A
  • Revenue
  • ENTX $181,000.00
  • IMRX N/A
  • Revenue This Year
  • ENTX N/A
  • IMRX N/A
  • Revenue Next Year
  • ENTX N/A
  • IMRX N/A
  • P/E Ratio
  • ENTX N/A
  • IMRX N/A
  • Revenue Growth
  • ENTX N/A
  • IMRX N/A
  • 52 Week Low
  • ENTX $1.41
  • IMRX $1.00
  • 52 Week High
  • ENTX $3.35
  • IMRX $3.83
  • Technical
  • Relative Strength Index (RSI)
  • ENTX 32.36
  • IMRX 37.66
  • Support Level
  • ENTX $1.85
  • IMRX $1.60
  • Resistance Level
  • ENTX $2.02
  • IMRX $1.91
  • Average True Range (ATR)
  • ENTX 0.11
  • IMRX 0.12
  • MACD
  • ENTX -0.01
  • IMRX -0.00
  • Stochastic Oscillator
  • ENTX 10.87
  • IMRX 4.65

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: